---
title: "WHO expands access to lifesaving sickle cell treatment and child-friendly medicines"
id: "who-0-0-who-moves-to-expand-access-to-lifesaving-sickle-cell-treatment-and-care-for"
canonical_url: "https://medichelpline.com/clinical-feed/who-0-0-who-moves-to-expand-access-to-lifesaving-sickle-cell-treatment-and-care-for"
content_type: "clinical_feed_article"
specialty: "Pediatrics"
source_name: "World Health Organization"
source_url: "https://www.who.int/news/item/01-09-2026-who-moves-to-expand-access-to-lifesaving-sickle-cell-treatment-and-care-for-children"
published_at: "2026-09-01T11:31:29.000Z"
evidence_level: "Departmental update"
license: "CC-BY-NC-4.0 / Informational Use"
---
# WHO expands access to lifesaving sickle cell treatment and child-friendly medicines
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/who-0-0-who-moves-to-expand-access-to-lifesaving-sickle-cell-treatment-and-care-for
- **Specialty:** [Pediatrics](https://medichelpline.com/clinical-feed/pediatrics.md)
- **Primary Source:** World Health Organization
- **Source URL:** [Original Journal Publication](https://www.who.int/news/item/01-09-2026-who-moves-to-expand-access-to-lifesaving-sickle-cell-treatment-and-care-for-children)
- **Published At:** 2026-09-01T11:31:29.000Z
- **Evidence Rating:** Departmental update
## Executive GIST (TL;DR)
- Sickle cell disease (SCD) remains a leading cause of preventable childhood death and disability; an estimated **81,100** deaths occurred among children under five in 2021. - The WHO published its first normative guideline for diagnosis, prevention and clinical management of SCD in children and adolescents (0–19 years) in May 2026, with 15 recommendations across seven priority areas. - WHO issues a strong recommendation for the use of **hydroxyurea** for all children and adolescents with sickle cell anaemia aged 9 months to 19 years, irrespective of clinical severity. - WHO paired clinical guidance with efforts to improve availability of **quality-assured, child-friendly medicines**, prioritizing sub-Saharan Africa where nearly 80% of SCD cases occur. - The WHO Department of Sexual, Reproductive, Maternal, Child and Adolescent Health and Ageing collaborated with the Global Accelerator for Paediatric Formulations (GAP-f) to bridge guidance and medicine access. - The Paediatric Drug Optimization for sickle cell disease (PADO-SCD) exercise convened in September 2025 identified priority medicines and formulations, set a watch list of investigational therapies, and informed research priorities. - A **Target Product Profile (TPP) for paediatric hydroxyurea** published July 2026 defines preferred and minimum characteristics for age-appropriate formulations (dosage form, strengths, dosing flexibility, administration, stability, packaging and affordability) with emphasis on weight-based dosing and resource-limited settings. - The TPP underpins the first-ever **WHO Prequalification Expression of Interest (EOI)** for SCD therapeutics, making certain hydroxyurea formulations, including paediatric forms and 500 mg capsules, eligible for prequalification evaluation. - WHO encourages manufacturers to engage with the Prequalification of Medicines Team about eligibility, development requirements and submission pathways. - WHO is monitoring and preparing for a changing therapeutic landscape, including new medicines, biologics and gene therapies; PADO-SCD developed a watch list of promising investigational therapies and paediatric evidence priorities. - WHO stresses that effective medicines must be affordable, accessible and presented in child-appropriate formulations to translate recommendations into lives saved.
## Clinical Analysis & Structured Key Points
[Skip to main content](https://www.who.int/news/item/01-09-2026-who-moves-to-expand-access-to-lifesaving-sickle-cell-treatment-and-care-for-children#content) * [ ![World Health Organization](https://www.who.int/images/default-source/fallback/header-logos/h-logo-blue1820eae93c154e37b2588ab90fdbc17e.svg?sfvrsn=aaed4f35_20) ](https://www.who.int/) [Global](https://www.who.int/) * [Regions](https://www.who.int/news/item/01-09-2026-who-moves-to-expand-access-to-lifesaving-sickle-cell-treatment-and-care-for-children) ![World Health Organization](https://www.who.int/images/default-source/fallback/header-logos/h-logo-blue1820eae93c154e37b2588ab90fdbc17e.svg?sfvrsn=aaed4f35_20) WHO Regional websites * [ Africa ](https://www.afro.who.int/) * [ Americas ](https://www.paho.org/en) * [ South-East Asia ](https://www.who.int/southeastasia) * [ Europe ](https://www.who.int/europe/) * [ Eastern Mediterranean ](http://www.emro.who.int/index.html) * [ Western Pacific ](https://www.who.int/westernpacific/) When autocomplete results are available use up and down arrows to review and enter to select. Select language Select language English العربية 中文 Français Русский Español Português [ ![Home](https://www.who.int/ResourcePackages/WHO/assets/dist/images/logos/en/h-logo-blue.svg) ](https://www.who.int/ "Home") * [Home](https://www.who.int/) * [Health Topics](https://www.who.int/mega-menu/health-topics) * [All topics](https://www.who.int/health-topics/) * [A](https://www.who.int/health-topics/#A) * [B](https://www.who.int/health-topics/#B) * [C](https://www.who.int/health-topics/#C) * [D](https://www.who.int/health-topics/#D) * [E](https://www.who.int/health-topics/#E) * [F](https://www.who.int/health-topics/#F) * [G](https://www.who.int/health-topics/#G) * [H](https://www.who.int/health-topics/#H) * [I](https://www.who.int/health-topics/#I) * [J](https://www.who.int/health-topics/#J) * [K](https://www.who.int/health-topics/#K) * [L](https://www.who.int/health-topics/#L) * [M](https://www.who.int/health-topics/#M) * [N](https://www.who.int/health-topics/#N) * [O](https://www.who.int/health-topics/#O) * [P](https://www.who.int/health-topics/#P) * [Q](https://www.who.int/health-topics/#Q) * [R](https://www.who.int/health-topics/#R) * [S](https://www.who.int/health-topics/#S) * [T](https://www.who.int/health-topics/#T) * [U](https://www.who.int/health-topics/#U) * [V](https://www.who.int/health-topics/#V) * [W](https://www.who.int/health-topics/#W) * [X](https://www.who.int/health-topics/#X) * [Y](https://www.who.int/health-topics/#Y) * [Z](https://www.who.int/health-topics/#Z) * [Resources](https://www.who.int/mega-menu/health-topics/resources) * [Fact sheets](https://www.who.int/mega-menu/health-topics/resources/fact-sheets) * [Facts in pictures](https://www.who.int/mega-menu/health-topics/resources/facts-in-pictures) * [Multimedia](https://www.who.int/mega-menu/health-topics/resources/multimedia) * [Podcasts](https://www.who.int/mega-menu/health-topics/resources/podcasts) * [Publications](https://www.who.int/mega-menu/health-topics/resources/publications) * [Questions and answers](https://www.who.int/mega-menu/health-topics/resources/questions-and-answers) * [Tools and toolkits](https://www.who.int/mega-menu/health-topics/resources/tools-and-toolkits) * [Popular](https://www.who.int/mega-menu/health-topics/popular) * [Dengue](https://www.who.int/mega-menu/health-topics/popular/dengue) * [Endometriosis](https://www.who.int/mega-menu/health-topics/popular/endometriosis) * [Excessive heat](https://www.who.int/mega-menu/health-topics/popular/excessive-heat) * [Herpes](https://www.who.int/mega-menu/health-topics/popular/herpes) * [Mental disorders](https://www.who.int/mega-menu/health-topics/popular/mental-disorders) * [Mpox](https://www.who.int/mega-menu/health-topics/popular/mpox) * [Countries](https://www.who.int/mega-menu/countries) * [All countries](https://www.who.int/countries) * [A](https://www.who.int/countries/#A) * [B](https://www.who.int/countries/#B) * [C](https://www.who.int/countries/#C) * [D](https://www.who.int/countries/#D) * [E](https://www.who.int/countries/#E) * [F](https://www.who.int/countries/#F) * [G](https://www.who.int/countries/#G) * [H](https://www.who.int/countries/#H) * [I](https://www.who.int/countries/#I) * [J](https://www.who.int/countries/#J) * [K](https://www.who.int/countries/#K) * [L](https://www.who.int/countries/#L) * [M](https://www.who.int/countries/#M) * [N](https://www.who.int/countries/#N) * [O](https://www.who.int/countries/#O) * [P](https://www.who.int/countries/#P) * [Q](https://www.who.int/countries/#Q) * [R](https://www.who.int/countries/#R) * [S](https://www.who.int/countries/#S) * [T](https://www.who.int/countries/#T) * [U](https://www.who.int/countries/#U) * [V](https://www.who.int/countries/#V) * [W](https://www.who.int/countries/#W) * [X](https://www.who.int/countries/#X) * [Y](https://www.who.int/countries/#Y) * [Z](https://www.who.int/countries/#Z) * [Regions](https://www.who.int/mega-menu/countries/regions) * [Africa](https://www.who.int/mega-menu/countries/regions/africa) * [Americas](https://www.who.int/mega-menu/countries/regions/americas) * [Europe](https://www.who.int/mega-menu/countries/regions/europe) * [Eastern Mediterranean](https://www.who.int/mega-menu/countries/regions/eastern-mediterranean) * [South-East Asia ](https://www.who.int/mega-menu/countries/regions/south-east-asia) * [Western Pacific](https://www.who.int/mega-menu/countries/regions/western-pacific) * [WHO in countries](https://www.who.int/mega-menu/countries/who-in-countries) * [Data by country](https://www.who.int/mega-menu/countries/who-in-countries/data-by-country) * [Country presence ](https://www.who.int/mega-menu/countries/who-in-countries/country-presence) * [Country cooperation strategies ](https://www.who.int/mega-menu/countries/who-in-countries/country-cooperation-strategies) * [Country office profiles](https://www.who.int/mega-menu/countries/who-in-countries/country-office-profiles) * [Strengthening country offices ](https://www.who.int/mega-menu/countries/who-in-countries/country-strengthening) * [Newsroom](https://www.who.int/news-room) * [Newsroom](https://www.who.int/mega-menu/news/all-news) * [News releases](https://www.who.int/mega-menu/news/all-news/releases) * [Statements](https://www.who.int/mega-menu/news/all-news/statements) * [Campaigns](https://www.who.int/mega-menu/news/all-news/campaigns) * [Events](https://www.who.int/mega-menu/news/all-news/events) * [Feature stories](https://www.who.int/mega-menu/news/all-news/feature-stories) * [Speeches](https://www.who.int/mega-menu/news/all-news/speecheshub) * [Commentaries](https://www.who.int/mega-menu/news/all-news/commentaries) * [Photo library](https://www.who.int/mega-menu/news/all-news/photo-library) * [Headlines](https://www.who.int/news-room/headlines) * [Emergencies](https://www.who.int/mega-menu/emergencies) * [In focus](https://www.who.int/mega-menu/emergencies/emergencies) * [Cholera ](https://www.who.int/mega-menu/emergencies/emergencies/cholera) * [Ebola disease](https://www.who.int/mega-menu/emergencies/emergencies/ebola-disease) * [Israel and the occupied Palestinian territory](https://www.who.int/mega-menu/emergencies/emergencies/israel-and-occupied-palestinian-territory) * [Middle East](https://www.who.int/mega-menu/emergencies/emergencies/middle-east) * [Sudan](https://www.who.int/mega-menu/emergencies/emergencies/sudan) * [Ukraine](https://www.who.int/mega-menu/emergencies/emergencies/ukraine-emergency) * [Latest](https://www.who.int/mega-menu/emergencies/news) * [Disease Outbreak News](https://www.who.int/mega-menu/emergencies/news/disease-outbreak-news) * [Situation reports](https://www.who.int/mega-menu/emergencies/news/situation-reports) * [Rapid risk assessments](https://www.who.int/mega-menu/emergencies/news/rapid-risk-assessment) * [Weekly Epidemiological Record](https://www.who.int/mega-menu/emergencies/news/weekly-epidemiological-record) * [WHO in emergencies](https://www.who.int/mega-menu/emergencies/who-in-emergencies) * [Surveillance](https://www.who.int/mega-menu/emergencies/who-in-emergencies/surveillance) * [Alert and response](https://www.who.int/mega-menu/emergencies/who-in-emergencies/alert-and-response) * [Operations](https://www.who.int/mega-menu/emergencies/who-in-emergencies/operations) * [Research](https://www.who.int/mega-menu/emergencies/who-in-emergencies/research-development) * [Funding](https://www.who.int/mega-menu/emergencies/who-in-emergencies/funding) * [Partners](https://www.who.int/mega-menu/emergencies/who-in-emergencies/partners) * [Health emergency appeals](https://www.who.int/mega-menu/emergencies/who-in-emergencies/health-emergency-appeal) * [International Health Regulations](https://www.who.int/mega-menu/emergencies/who-in-emergencies/international-health-regulations) * [Independent Oversight and Advisory Committee](https://www.who.int/mega-menu/emergencies/who-in-emergencies/independent-oversight-and-advisory-committee) * [Data](https://www.who.int/mega-menu/data) * [Data at WHO](https://www.who.int/mega-menu/data/data-who) * [Data hub](https://www.who.int/mega-menu/data/data-who/data-hub) * [Global Health Estimates](https://www.who.int/mega-menu/data/data-who/global-health-estimates) * [Health inequality](https://www.who.int/mega-menu/data/data-who/health-inequality) * [Global Health Observatory](https://www.who.int/mega-menu/data/data-who/global-health-obsevatory) * [Dashboards](https://www.who.int/mega-menu/data/dashboards) * [Triple Billion Progress](https://www.who.int/mega-menu/data/dashboards/triple-billion-progress) * [Health Inequality Monitor](https://www.who.int/mega-menu/data/dashboards/health-inequality-monitor) * [Delivery for impact](https://www.who.int/mega-menu/data/dashboards/delivery-for-impact) * [COVID-19 dashboard](https://www.who.int/mega-menu/data/dashboards/covid-19-dashboard) * [Data collection](https://www.who.int/mega-menu/data/data-collection) * [Classifications](https://www.who.int/mega-menu/data/data-collection/classifications) * [SCORE](https://www.who.int/mega-menu/data/data-collection/score) * [Surveys](https://www.who.int/mega-menu/data/data-collection/surveys) * [Civil registration and vital statistics](https://www.who.int/mega-menu/data/data-collection/civil-registration-and-vital-statistics) * [Routine health information systems](https://www.who.int/mega-menu/data/data-collection/routine-health-information-systems) * [Harmonized health facility assessment](https://www.who.int/mega-menu/data/data-collection/harmonized-health-facility-assessment) * [GIS centre for health](https://www.who.int/mega-menu/data/data-collection/gis-centre-for-health) * [Reports](https://www.who.int/mega-menu/data/reports) * [World Health Statistics](https://www.who.int/mega-menu/data/reports/world-health-statistics) * [UHC global monitoring report](https://www.who.int/mega-menu/data/reports/uhc-global-monitoring-report) * [About WHO](https://www.who.int/mega-menu/about-us) * [About WHO](https://www.who.int/mega-menu/about-us/about) * [Partnerships](https://www.who.int/mega-menu/about-us/about/partnerships-and-collaboration) * [Committees and advisory groups](https://www.who.int/mega-menu/about-us/about/expert-groups) * [Collaborating centres](https://www.who.int/mega-menu/about-us/about/collaborating-centres) * [Technical teams](https://www.who.int/mega-menu/about-us/about/teams) * [Organizational structure](https://www.who.int/mega-menu/about-us/about/structure) * [Who we are](https://www.who.int/mega-menu/about-us/about/who-we-are) * [Our work](https://www.who.int/mega-menu/about-us/our-work) * [Activities](https://www.who.int/mega-menu/about-us/our-work/activities) * [Initiatives](https://www.who.int/mega-menu/about-us/our-work/initiatives) * [General Programme of Work](https://www.who.int/mega-menu/about-us/our-work/global-programme-of-work) * [WHO Academy](https://www.who.int/mega-menu/about-us/our-work/who-academy) * [Funding](https://www.who.int/mega-menu/about-us/who-funding) * [Investment in WHO](https://www.who.int/mega-menu/about-us/who-funding/investment-case) * [WHO Foundation](https://www.who.int/mega-menu/about-us/who-funding/who-foundation) * [Accountability](https://www.who.int/mega-menu/about-us/accountability) * [External audit](https://www.who.int/mega-menu/about-us/accountability/audit) * [Financial statements](https://www.who.int/mega-menu/about-us/accountability/financial-statements) * [Internal audit and investigations ](https://www.who.int/mega-menu/about-us/accountability/internal-audit-and-investigations) * [Programme Budget](https://www.who.int/mega-menu/about-us/accountability/budget) * [Results reports](https://www.who.int/mega-menu/about-us/accountability/results-report) * [Governance](https://www.who.int/mega-menu/about-us/governance) * [Governing bodies](https://www.who.int/mega-menu/about-us/governance/governing-bodies-website) * [World Health Assembly](https://www.who.int/mega-menu/about-us/governance/wha) * [Executive Board](https://www.who.int/mega-menu/about-us/governance/eb) * [Member States Portal](https://www.who.int/mega-menu/about-us/governance/member-states-portal) * [Home](https://www.who.int/)/ * [News](https://www.who.int/news)/ * [item](https://www.who.int/news/item)/ * WHO moves to expand access to lifesaving sickle cell treatment and care for children WHO/Tafadzwa Ufumeli © Credits # WHO moves to expand access to lifesaving sickle cell treatment and care for children 1 September 2026 Departmental update Reading time: 4 min (1030 words) Sickle cell disease contributed to an estimated 81 100 deaths among children under five in 2021. WHO is working to close that gap, pairing updated clinical guidance with new efforts to make quality-assured, child-friendly medicines more widely available, especially in sub-Saharan Africa, where nearly 80% of cases occur. “Too many children with sickle cell disease are still dying or suffering devastating complications, even though we have treatments that can help them. Our goal is simple: to make sure that where a child is born does not determine whether they can get the treatment they need to survive and live a healthy life. The new WHO package of guidance and tools is aimed at improving the care and treatment of children and adolescents living with sickle cell disease (SCD), while accelerating access to medicines that are appropriate, quality-assured and affordable,” said Dr Pascale Allotey, Director, Department of Sexual, Reproductive, Maternal, Child and Adolescent Health and Ageing, WHO. The work brings together WHO’s technical leadership on child and adolescent health and sickle cell disease from the Department of Sexual, Reproductive, Maternal, Child and Adolescent Health and Ageing in close collaboration with the Global Accelerator for Paediatric Formulations (GAP-f), hosted by the Science for Health Department. Together, these efforts span the pathway from evidence-based clinical guidance and identification of priority medicines, to defining the characteristics of appropriate paediatric formulations, establishing a pathway towards quality-assured products, and anticipating future therapeutic options for children. SCD is the most common inherited blood disorder worldwide and remains a leading cause of preventable childhood death and disability, particularly in low- and middle-income countries. The burden is greatest in sub-Saharan Africa, although SCD also affects populations in the Eastern Mediterranean, the Caribbean, South Asia, Latin America and increasingly diaspora populations worldwide. “Having an effective medicine is not enough if children cannot get it, afford it or take it in a form designed for them. Together with our partners, we are working to change that for sickle cell disease, starting with hydroxyurea, a medicine that can prevent serious complications and save lives,” said Meg Doherty, Director of the Department of Science for Health at WHO. Despite the availability of effective interventions, major inequities persist in access to early diagnosis, comprehensive care and disease-modifying treatment. Over the past year, WHO has taken a series of complementary steps to address these gaps. ## From clinical guidance to better medicines for children with SCD In May 2026, WHO published its first [normative guideline specifically addressing the diagnosis, prevention and clinical management of SCD in children and adolescents aged 0–19 years](https://www.who.int/publications/i/item/9789240122666). It includes 15 recommendations across seven priority areas, including a strong recommendation for the use of hydroxyurea for all children and adolescents with sickle cell anaemia aged 9 months to 19 years, regardless of clinical severity. Recognizing that clinical recommendations need to be matched by availability and access to medicines that children can actually receive and use appropriately, the WHO Department of Sexual, Reproductive, Maternal, Child and Adolescent Health and Ageing and the Global Accelerator for Paediatric formulations convened the first [Paediatric Drug Optimization for sickle cell disease (PADO-SCD)](https://www.who.int/publications/i/item/B09861) exercise in September 2025. The exercise identified priority medicines and formulations for currently available treatments, including hydroxyurea, and established a watch list of promising investigational therapies and related research priorities. The PADO-SCD exercise identified hydroxyurea as an immediate priority for expanding access for its use in this age group in line with the latest WHO guidelines and informed the development of a [Target Product Profile (TPP) for paediatric hydroxyurea](https://www.who.int/publications/i/item/B09727). Published in July 2026, the TPP defines the preferred and minimum characteristics for age-appropriate formulations, including dosage form, strengths, dosing flexibility, administration, stability, packaging and affordability, with an emphasis on paediatric-friendly forms suitable for flexible weight-based dosing and use in resource-limited settings. The TPP has informed the first-ever [WHO Prequalification Expression of Interest for SCD therapeutics](https://extranet.who.int/prequal/news/1st-invitation-manufacturers-therapeutics-sickle-cell-disease-submit-expression-interest-eoi) (EOI), translating identified product needs into formulations of hydroxyurea eligible for WHO prequalification evaluation, including paediatric formulations as well as 500 mg hydroxyurea capsules. WHO encourages manufacturers to review the EOI and engage with the WHO Prequalification of Medicines Team regarding eligibility, development requirements and submission pathways. ## Looking ahead to a changing SCD treatment landscape WHO is also looking beyond today’s treatment options. The therapeutic landscape for SCD is evolving rapidly, with new medicines, biologics and potentially transformative technologies, including gene therapies, under development. Through the PADO-SCD exercise, WHO reviewed emerging products in the research and development pipeline and developed a watch list of promising investigational therapies together with priorities for future research. This forward-looking work aims to ensure that paediatric evidence requirements, access considerations and the realities of high-burden,
## Related Clinical Research

- [Childhood pneumonia after vaccines: shifting pathogen mix and the case for platform investments](https://medichelpline.com/clinical-feed/medrxiv-22-after-the-vaccine-era-sequencing-platform-investments-as-the-childhood.md)
- [How pediatricians build trust with vaccine-hesitant parents — a practice of last resort](https://medichelpline.com/clinical-feed/stat-news-3-the-pediatricians-who-take-in-vaccine-skeptical-parents-others-won-t.md)
- [Young children's behavior changes after COVID-19 onset: longitudinal findings from three US cities](https://medichelpline.com/clinical-feed/pubmed-41891858.md) (DOI: 10.1093/chidev/aacag016)
- [Reading achievement in under-resourced K–2 students before, during, and after COVID-19 disruptions](https://medichelpline.com/clinical-feed/pubmed-42605168.md) (DOI: 10.1093/chidev/aacag146)
- [WHO validates Bhutan for eliminating dog-transmitted human rabies](https://medichelpline.com/clinical-feed/who-0-0-who-validates-bhutan-for-eliminating-dog-transmitted-human-rabies.md)

## Navigation
- [← Back to Pediatrics Feed](https://medichelpline.com/clinical-feed/pediatrics.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.